Kidney drug study aims to unlock heart benefits

NCT ID NCT05719714

First seen Apr 15, 2026 · Last updated Apr 28, 2026 · Updated 2 times

Summary

This study looks at how dapagliflozin, a drug used for diabetes, affects the heart and metabolism in people with chronic kidney disease. Researchers will measure heart function and blood markers in 60 adults. The goal is to understand how the drug works, not to test a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60607, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.